Analysis of drug use in young-onset and late-onset patients with type 2 diabetes mellitus in southwestern China based on the YiduCloud database.

Abstract

Abstract Aims We aim to compare the clinical features and drug use between young-onset diabetics (YOD)and late-onset diabetics (LOD) to provide the lack of information in the diagnosis and treatment of type 2 diabetes mellitus patients in southwestern China. Methods In this cross-sectional study, data of T2DM patients in the YiduCloud database of Chongqing from January ,2019 to December was involved. The comparative analysis of drug use between YOD and LOD included single, dual and triple drug treatments. Logistic regression was used to explore the related factors of combined drug use. Results A total of 5552 cases of T2DM were identified. The proportion of drug use was: single drug:1390 (25.0%); dual drugs:1480 (26.6%); triple drugs:1406 (25.3%) four or more drugs:1276 (23.0%). The mostly used drugs were insulin (64.1%), metformin (47.5%), alpha-glucosidase inhibitors (34.9%), sodium-dependent glucose transporters 2 inhibitors (19.3%) and sulfonylureas (18.0%). Dual use of drugs accounted for the largest proportion of combined drugs (16.6%), in which insulin with metformin took the greatest part (21.1%), followed by metformin with sulfonylureas (12.0%). Among the triple drugs, most (19.6%) were metformin with insulin and dipeptidyl peptidase-4 inhibitors followed by metformin with insulin and alpha-glucosidase inhibitors (14.9%). There were significant differences in single and combined drug use between YOD and LOD (P < 0.001) especially in triple drugs(P < 0.001). Logistic regression showed that gender, nationality, type of diabetes (YOD and LOD), number of complications and abnormal glycosylated hemoglobin at admission were significant related factors of combined drug use (P < 0.001). Conclusions There is a significant difference in clinical features and drug use between YOD and LOD. Our study is of significance for providing more scientific diagnosis and treatment for patients by identifying the characteristics of high-risk groups with YOD.